Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

FAST_TOX

Financiado

BANKED HEPATOCYTE MONOLAYERS FOR ACCELERATING DRUG TOXICITY SCREENING

This proof of concept grant will transform how liver cells are cryopreserved for the toxicological testing market, translating scientific findings emerging from an ERC starter grant from lab to real application. During the drug di... ver más

28/02/2023

UNIVERSITY OF WARW...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITY OF WARWICK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-02-28

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

UNIVERSITY OF WARWICK

150.00K€ | Lider

MADERAS JOSE SAIZ, S.L.

757.37K€ | Participante

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 37 meses Fecha Inicio: 2020-01-28
Fecha Fin: 2023-02-28

Líder del proyecto

UNIVERSITY OF WARWICK

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto This proof of concept grant will transform how liver cells are cryopreserved for the toxicological testing market, translating scientific findings emerging from an ERC starter grant from lab to real application. During the drug discovery process, the leading cause of new candidate drug rejection is the discovery of an unfavourable toxicological profile. It is essential to discover these as early as possible in the process to minimize costs and ensure favourable candidates are taken forward and to reduce the need for animal experimentation. The current standard screening method is using isolated hepatocyte (liver cells) to screen for toxicity. There is a disconnect however, in that these cells must be stored frozen in suspension, but all testing is undertaken on the cells grown attached to scaffolds as monolayers. It is not currently possible to cryopreserve cells as monolayers, and hence there is significant (time and financial) effort involved in processing, plating and growing the cells, acting as a bottleneck. This project will use unique cryoprotective polymers, developed in an ERC starter grant, to enable the cryopreservation of hepatocytes directly on the tissue culture plastic, enabling for the first time banking of the cells in an ‘assay-ready format’. We have established strong preliminary data demonstrating this concept in other cell lines, and have filed patents and shown the synthesis can be scaled up. In this project we will obtained essential data sets to demonstrate industrially-relevant cryopreservation of hepatocytes, but also emerging 3-D hepatocyte models (spheroids) to de-risk industrial translation and trigger licensing or investment. This will include not just scientific data but a cost-benefit analysis showing the economic gains due to reduced personnel effort required. There will be significant economic, but also societal benefit in optimising toxicological screening to improve the drug discovery process.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores